Navigation Links
Amneal Pharmaceuticals & Indoco Remedies Finalize Long Term Joint Venture Agreement to Develop and Market Generic Ophthalmic Pharmaceuticals
Date:10/23/2007

rowing generic company as a partner to market our ophthalmic products in the USA. This partnership will help us to speedily introduce these products to the US market and explore other growth opportunities in the largest generic market of the world," said Mr. Suresh G. Kare, chairman & managing director of Indoco Remedies Limited.

Indoco and Amneal have already begun to identify several more ophthalmic products to pursue as well as other therapeutic categories and dosage forms. The two companies fully expect this agreement to expand significantly in the near term and to last many years.

With balanced input from both Amneal and Indoco, funding for developing these products will be equally shared. Likewise, the financial benefit from the sale of these products will be shared for years.

INDOCO REMEDIES Limited, headquartered in India, is a fully integrated research based pharmaceutical company, producing a wide range of high quality, affordable generic medicines trusted across the Globe. Indoco enjoys a dominant position in the domestic Indian market and its products are distributed in over 30 countries, including USA, Germany, UK and Australia. The state-of-the-art R&D facilities cover 70,000 sq ft, employ 100 scientists and support a manufacturing plant with approvals from USFDA, UK-MHRA, German Regulatory Authorities and ANVISA Brazil, reflecting the Company's commitment to being a leader in the generic space worldwide.

AMNEAL PHARMACEUTICALS LLC, headquartered in Paterson, NJ, is a USA-based firm that develops, manufacturers and distributes generic pharmaceutical products regulated and approved by the US FDA. Positioned as "Generic's New Generation," the company utilizes diverse R&D and manufacturing expertise to conceive breakthrough developments with lasting impact. Vigorous ANDA growth and broad product acquisitions are keys of Amneal's strategic growth plan, as is the company's commitment to building deep relationships with its customer b
'/>"/>

SOURCE Amneal Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Supply of Radiopharmaceuticals Hampered by Attacks
2. FDA approves Watson Pharmaceuticals Oxytrol patch
3. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
4. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
5. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
6. Top Pharmaceuticals Influence Doctors Prescriptions
7. More Study On Side Effects of ADHD Drug Needed: Shire Pharmaceuticals
8. Personalized Medicine and Innovative Pharmaceuticals
9. New lease of life for asthmatics by Accentia Biopharmaceuticals
10. Pravastatin Launched by Watson Pharmaceuticals
11. Tata Industries picks up stake in Indigene Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... April 17, 2015 Representatives Jim Himes ... and Treatment Act HR 1849 in congress on April ... and treatment for patients with the genetic disease. ... past, would be the first to create a federally ... treatment of hereditary hemorrhagic telangiectasia. This would effectively prevent ...
(Date:4/17/2015)... 17, 2015 As a board-certified orthopedic ... new offering of platelet-rich plasma (PRP) and ... is known for its world-class care of injury-caused ... surgical experience lacking in many other physicians offering regenerative ... are utilized for pain management and rehabilitation. Dr. Meier ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 Most dental ... dental restoration units are made overseas by foreign dental ... domestic labs remain unregulated in more than 40 states ... National Association of Dental Laboratories has created ... raise awareness among patients about the consequences that could ...
(Date:4/17/2015)... Baptist Health and The University of Texas MD ... to transform oncology care in northeast Florida and southeast ... a joint cancer program to enhance patient access to ... Anderson Cancer Center is anticipated to open in the ... coordinated, multidisciplinary cancer care for adults in the region. ...
(Date:4/17/2015)... York, NY (PRWEB) April 17, 2015 ... collaborating with a multicenter team of U.S. and ... of bacteria yet in humans among an isolated ... jungles of Venezuela. Bacterial diversity in the Yanomami, ... found to be nearly double that of people ...
Breaking Medicine News(10 mins):Health News:House Representatives Introduce Bill to Fight Genetic Disease 2Health News:Platelet-Rich Plasma, Stem Cell Therapy Now Offered By Dr. Meier At MOSM in Beverly Hills, California 2Health News:Platelet-Rich Plasma, Stem Cell Therapy Now Offered By Dr. Meier At MOSM in Beverly Hills, California 3Health News:National Association Urges Transparency in Dental Industry 2Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 2Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 3Health News:Mount Sinai Scientists Find Unprecedented Microbial Diversity in Isolated Amazonian Tribe Previously Unexposed to Antibiotics or Processed Foods 2Health News:Mount Sinai Scientists Find Unprecedented Microbial Diversity in Isolated Amazonian Tribe Previously Unexposed to Antibiotics or Processed Foods 3
... devouring billions of dollars globally, Alzheimer,s disease is the ... Although intensely investigated over the last three decades using ... not been found. While many research "breakthroughs" have ... does the promised "cure" still seem to elude scientists? ...
... (HealthDay News) -- Good news for high-mileage runners: They may be ... because variations in diet are less likely to affect them, researcher ... grouped according to the distance they run each day: less than ... to 4 km); 2.4 to 3.7 miles (4 to 6 km); ...
... published research shows that more patients with end-stage ... hemodialysis as their initial kidney replacement therapy over ... the study now available in Arthritis Care ... College of Rheumatology (ACR), also found that African ...
... device that combines two microimaging technologies can reveal ... biological activities that, in coronary arteries, could indicate ... of clots in arterial stents. In their ... Massachusetts General Hospital (MGH) investigators describe using an ...
... Special Surgery physician-scientists who focus on arthritis, lupus, vasculitis ... to Chicago this week to share their recent findings ... College of Rheumatology (ACR). Special Surgery investigators will ... care. Of the meeting,s highlights, results from the nine-year ...
... appear to be stopping anti-TNF medications before surgery, but may ... a new study by researchers at Hospital for Special Surgery. ... diseases, including rheumatoid arthritis, and better timing of withdrawal prior ... "We need to do more studies to see ...
Cached Medicine News:Health News:New study challenges accepted approaches to research in senile dementia (Alzheimer's disease) 2Health News:New study challenges accepted approaches to research in senile dementia (Alzheimer's disease) 3Health News:Runners Can Relax About Holiday Feasting: Study 2Health News:Most lupus nephritis patients with end-stage renal disease opt for hemodialysis therapy 2Health News:Combined arterial imaging technology reveals both structural and metabolic details 2Health News:Hospital for special surgery physician-scientists share advances in rheumatology research 2Health News:Hospital for special surgery physician-scientists share advances in rheumatology research 3Health News:Hospital for special surgery physician-scientists share advances in rheumatology research 4Health News:Hospital for special surgery physician-scientists share advances in rheumatology research 5Health News:Hospital for special surgery physician-scientists share advances in rheumatology research 6Health News:Tweaking withdrawal of rheumatoid arthritis medications before surgeries may reduce disease flares 2Health News:Tweaking withdrawal of rheumatoid arthritis medications before surgeries may reduce disease flares 3
(Date:4/16/2015)... , April 16, 2015 Today, Kenneth ... Merck & Co., Inc., was elected chairman of the Board ... today,s Board meeting, PhRMA,s president and CEO John J. ... 1, 2016.  New Officers Elected to PhRMA ... and succeeds Ian C. Read , chairman and CEO ...
(Date:4/16/2015)... April 16, 2015  Rosewind Corporation (OTCMKTS: RSWN) ... merger with a newly formed specialty healthcare company ... on addressing urological disorders. The merged company, which ... has commenced operations and incorporates the pipeline assets ... Company,s strategy is to build a late-stage and ...
(Date:4/16/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/qvd3lm/cancer_growth ) ... Growth Inhibitors Market & Clinical Pipeline Analysis " ... growth inhibitors market shows overlapping boundaries due to ... For instance, a tyrosine kinase may be a ... have same inhibitory molecule. On the other hand, ...
Breaking Medicine Technology:Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 2Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 3Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 4Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman 5Rosewind Corporation Shifts Focus to Develop Late-Stage Therapeutics for Urological and Related Conditions 2Rosewind Corporation Shifts Focus to Develop Late-Stage Therapeutics for Urological and Related Conditions 3Global Cancer Growth Inhibitors Market & Clinical Pipeline Analysis 2015 2Global Cancer Growth Inhibitors Market & Clinical Pipeline Analysis 2015 3
... 28, 2011 Uroplasty, Inc. (NASDAQ: UPI ), ... proprietary products to treat voiding dysfunctions, today reported financial results ... 2011. Global sales grew 53% to $4.7 million ... with $3.0 million in the fiscal first quarter a year ...
... 28, 2011 Codexis, Inc. (Nasdaq: CDXS ... wholly-owned by Italy,s Gruppo Mossi & Ghisolfi ("M&G Group"), ... sustainable detergent alcohols for use in the household products ... alcohols from cellulosic (non-food) biomass. Detergent alcohols ...
Cached Medicine Technology:Uroplasty Reports Financial Results for the First Quarter of Fiscal 2012 2Uroplasty Reports Financial Results for the First Quarter of Fiscal 2012 3Uroplasty Reports Financial Results for the First Quarter of Fiscal 2012 4Uroplasty Reports Financial Results for the First Quarter of Fiscal 2012 5Uroplasty Reports Financial Results for the First Quarter of Fiscal 2012 6Uroplasty Reports Financial Results for the First Quarter of Fiscal 2012 7Uroplasty Reports Financial Results for the First Quarter of Fiscal 2012 8Codexis and Chemtex to Collaborate on Sustainable Detergent Alcohols for the Household Products Market 2Codexis and Chemtex to Collaborate on Sustainable Detergent Alcohols for the Household Products Market 3Codexis and Chemtex to Collaborate on Sustainable Detergent Alcohols for the Household Products Market 4
The RU is a low profile implantable bipolar tined permanent pacing lead for stimulation of either the atrium (J model) or the ventricle (straight model)....
The Petite leads are low profile (4.8F lead body diameter) implantable endocardial pacing leads which are manufactured using a new proprietary hexafilar coil for permanent stimulation of the ventricl...
The Vitatron Excellence S+ lead series are endocardial leads providing excellent reliability and optimal pacing characteristics....
... Impulse II lead series are silicon ... extend the longevity of the pacemaker ... The high impedance of the lead ... electrode surface, combined with the elution ...
Medicine Products: